Biotech breakthrough: Mersana Therapeutics stock soars 23% after blowing past Q3 expectations
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, saw its shares leap by 23% following a robust third-quarter earnings report that surpassed Wall Street’s expectations. Investors and analysts alike have taken note, as Mersana Therapeutics’ financial results not only demonstrate strong revenue growth but also highlight strategic […]
